Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach.
cocaine
cocaine use disorder
prescription amphetamines
stimulants, dopaminergic agonists
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
2023
2023
Historique:
revised:
20
12
2022
received:
30
05
2022
accepted:
13
02
2023
pmc-release:
01
01
2024
medline:
6
4
2023
entrez:
5
4
2023
pubmed:
6
4
2023
Statut:
ppublish
Résumé
Cocaine use is a public health concern in many countries worldwide, particularly in the Americas and Oceania. Overdose deaths involving stimulants, such as cocaine, have been increasing markedly in North America, especially with concurrent opioid involvement. To date, no pharmacological treatment is available to treat stimulant (including cocaine) use disorders. Prescription psychostimulants (PPs) could be useful to treat cocaine use disorder (CUD) as they share the pharmacological effects with cocaine, as evidenced by a recent meta-analysis that assessed 38 randomized clinical trials (RCTs). PPs were found to promote sustained abstinence and reduce drug use in patients with CUD. The aim of this paper is to provide a narrative review of the clinical pharmacology of PPs and comment on the current stage of evidence supporting PPs to treat CUD. We also propose a model of care that integrates PPs with evidence-based psychosocial interventions (such as cognitive-behavioural therapy [CBT] and contingency management [CM]), a harm reduction approach and case management with social support.
Identifiants
pubmed: 37016755
doi: 10.1111/adb.13271
pmc: PMC10499006
mid: NIHMS1928539
doi:
Substances chimiques
Central Nervous System Stimulants
0
Prescription Drugs
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13271Subventions
Organisme : NIDA NIH HHS
ID : K99 DA049886
Pays : United States
Organisme : NIDA NIH HHS
ID : R00 DA049886
Pays : United States
Informations de copyright
© 2023 Society for the Study of Addiction.
Références
Drug Alcohol Depend. 2019 Aug 1;201:227-235
pubmed: 31254749
Neuropsychopharmacology. 2021 Jan;46(2):305-315
pubmed: 32682325
Cochrane Database Syst Rev. 2016 Mar 19;3:CD006306
pubmed: 26992929
J Dual Diagn. 2017 Jul-Sep;13(3):219-229
pubmed: 28414579
Mol Neurobiol. 1995 Aug-Dec;11(1-3):1-19
pubmed: 8561954
J Psychoactive Drugs. 2022 Jan-Mar;54(1):25-33
pubmed: 33749541
Adv Pharmacol. 2014;69:129-76
pubmed: 24484977
Future Med Chem. 2012 Feb;4(2):245-65
pubmed: 22300101
Neuropsychopharmacology. 2018 Jul;43(8):1753-1762
pubmed: 29703999
Biol Psychiatry. 2020 Jan 1;87(1):82-88
pubmed: 31420089
Addiction. 2016 Aug;111(8):1337-46
pubmed: 26826006
Am J Psychiatry. 2000 Jul;157(7):1134-40
pubmed: 10873923
Addiction. 2020 Sep;115(9):1683-1694
pubmed: 32096302
Addiction. 2014 Sep;109(9):1414-25
pubmed: 24995905
J Subst Abuse Treat. 2021 Mar;122:108219
pubmed: 33353790
J Gen Intern Med. 2019 Dec;34(12):2858-2873
pubmed: 31183685
J Chem Neuroanat. 2000 Dec;20(3-4):271-80
pubmed: 11207425
Lancet. 2016 May 28;387(10034):2226-34
pubmed: 27015909
J Subst Abuse Treat. 2016 Sep;68:74-82
pubmed: 27431050
Neuropsychopharmacology. 2015 Jul;40(8):1826-36
pubmed: 25689882
Harm Reduct J. 2020 Jan 10;17(1):6
pubmed: 31924209
J Pharmacol Exp Ther. 1994 Dec;271(3):1678-85
pubmed: 7996484
JAMA Psychiatry. 2020 Nov 1;77(11):1105-1106
pubmed: 32667643
Subst Abuse Treat Prev Policy. 2011 Feb 14;6:3
pubmed: 21320347
Subst Abuse Treat Prev Policy. 2007 Mar 29;2:10
pubmed: 17394653
Psychopharmacology (Berl). 2010 Jun;210(3):439-48
pubmed: 20386883
CNS Drugs. 2020 Apr;34(4):337-365
pubmed: 32185696
Am J Drug Alcohol Abuse. 1985;11(3-4):193-7
pubmed: 4091158
PLoS One. 2020 Jun 18;15(6):e0234809
pubmed: 32555667
Addiction. 2018 Jan;113(1):146-147
pubmed: 29226534
Pharmacol Biochem Behav. 1990 Jan;35(1):237-44
pubmed: 2315363
Drug Alcohol Depend. 2016 Nov 01;168:263-273
pubmed: 27736680
Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380
pubmed: 27670244
Prog Mol Biol Transl Sci. 2011;98:1-46
pubmed: 21199769
Drug Alcohol Depend. 2014 May 1;138:225-8
pubmed: 24629632
J Neurosci. 2001 Apr 15;21(8):2799-807
pubmed: 11306632
Cureus. 2018 Sep 18;10(9):e3328
pubmed: 30473961
Acta Psychiatr Scand. 1990 Sep;82(3):223-7
pubmed: 2248048
Drug Alcohol Depend. 1993 Jan;31(2):149-58
pubmed: 8436060
Behav Res Ther. 2018 Dec;111:57-63
pubmed: 30316027
Addiction. 2016 May;111(5):767-74
pubmed: 26503542
J Phys Chem B. 2009 Nov 12;113(45):15057-66
pubmed: 19831380
J Clin Psychopharmacol. 1997 Dec;17(6):485-8
pubmed: 9408812
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
Drug Alcohol Depend. 2020 Jan 1;206:107700
pubmed: 31753736
J Consult Clin Psychol. 2021 Jan;89(1):58-71
pubmed: 33507776
JAMA Netw Open. 2021 May 3;4(5):e218049
pubmed: 33961037
Eur Addict Res. 2011;17(2):80-9
pubmed: 21178355
Clin Toxicol (Phila). 2015 Jun;53(5):477-85
pubmed: 25832473
BMJ Open. 2021 May 18;11(5):e044696
pubmed: 34006547
Addiction. 2017 Dec;112(12):2191-2201
pubmed: 28603836
Neuropsychopharmacology. 2008 Jan;33(2):219-25
pubmed: 17443127
JAMA. 2020 Jul 7;324(1):39-40
pubmed: 32459292
Addict Behav. 2014 Jan;39(1):297-301
pubmed: 24455783
Behav Processes. 2012 May;90(1):142-53
pubmed: 22421220
J Pharmacol Exp Ther. 2002 Mar;300(3):831-7
pubmed: 11861788
Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255
pubmed: 32601988
Int J Drug Policy. 2015 Apr;26(4):352-63
pubmed: 25662894
Am J Drug Alcohol Abuse. 2021 May 4;47(3):402-409
pubmed: 33797985
Clin Pharmacol Ther. 2011 Feb;89(2):276-82
pubmed: 21178989
Trends Pharmacol Sci. 1992 May;13(5):193-200
pubmed: 1604712
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1601-13
pubmed: 17888557
JAMA Psychiatry. 2021 Dec 1;78(12):1329-1342
pubmed: 34550301
PLoS Med. 2018 Dec 26;15(12):e1002715
pubmed: 30586362
Addiction. 2014 Sep;109(9):1426-36
pubmed: 24750232
J Pharmacol Exp Ther. 1995 Dec;275(3):1551-9
pubmed: 8531128
Drug Alcohol Depend. 2015 Jul 1;152:62-7
pubmed: 25982007
Ann N Y Acad Sci. 1992 Jun 28;654:171-91
pubmed: 1632582
Biochem Pharmacol. 2008 Jan 1;75(1):196-217
pubmed: 17825265
J Subst Abuse Treat. 1984;1(2):107-12
pubmed: 6536756
Biochim Biophys Acta. 1993 Oct 4;1144(3):249-63
pubmed: 8104483
Int J Drug Policy. 2015 Dec;26(12):1177-82
pubmed: 26500166
Drug Alcohol Depend. 2016 Jan 1;158:1-7
pubmed: 26652899
J Consult Clin Psychol. 2016 Oct;84(10):907-12
pubmed: 27454780
J Neurosci. 2018 Jan 10;38(2):484-497
pubmed: 29175958
Psychopharmacology (Berl). 2017 Sep;234(17):2607-2617
pubmed: 28584928
Neuropharmacology. 2011 Jul-Aug;61(1-2):245-51
pubmed: 21521647
Brain Res. 1993 Nov 19;628(1-2):17-25
pubmed: 8313144
Addiction. 2010 Jan;105(1):146-54
pubmed: 19839966
Psychopharmacology (Berl). 1997 May;131(1):40-8
pubmed: 9181634
Eur J Pharmacol. 2000 Oct 6;406(1):1-13
pubmed: 11011026
Ann Intern Med. 2017 Feb 21;166(4):268-278
pubmed: 27919103
Forensic Sci Med Pathol. 2021 Jun;17(2):208-215
pubmed: 33237521
Addiction. 2020 May;115(5):946-958
pubmed: 31912625
Am J Psychiatry. 1983 Jun;140(6):784-5
pubmed: 6846640